|
1
|
Mirabello L, Troisi RJ and Savage SA:
International osteosarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int J Cancer.
125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Valery PC, Laversanne M and Bray F: Bone
cancer incidence by morphological subtype: A global assessment.
Cancer Causes Control. 26:1127–1139. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qureshi A, Ahmad Z, Azam M and Idrees R:
Epidemiological data for common bone sarcomas. Asian Pac J Cancer
Prev. 11:393–395. 2010.PubMed/NCBI
|
|
4
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: An analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anderson ME: Update on survival in
osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar
|
|
6
|
Ferrari S and Serra M: An update on
chemotherapy for osteosarcoma. Expert Opin Pharmacother.
16:2727–2736. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Akiyama T, Dass CR and Choong PF: Novel
therapeutic strategy for osteosarcoma targeting osteoclast
differentiation, bone-resorbing activity, and apoptosis pathway.
Mol Cancer Ther. 7:3461–3469. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen X, Fan S and Song E: Noncoding RNAs:
New players in cancers. Adv Exp Med Biol. 927:1–47. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xie CH, Cao YM, Huang Y, Shi QW, Guo JH,
Fan ZW, Li JG, Chen BW and Wu BY: Long non-coding RNA TUG1
contributes to tumorigenesis of human osteosarcoma by sponging
miR-9-5p and regulating POU2F 1 expression. Tumour Biol.
37:15031–15041. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khorkova O, Hsiao J and Wahlestedt C:
Basic biology and therapeutic implications of lncRNA. Adv Drug
Deliv Rev. 87:15–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Prensner JR, Iyer MK, Sahu A, Asangani IA,
Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, et al:
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer
and antagonizes the SWI/SNF complex. Nat Genet. 45:1392–1398. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wilusz JE: Long noncoding RNAs: Re-writing
dogmas of RNA processing and stability. Biochim Biophys Acta.
1859:128–138. 2016. View Article : Google Scholar
|
|
16
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kapranov P, Cheng J, Dike S, Nix DA,
Duttagupta R, Willingham AT, Stadler PF, Hertel J, Hackermüller J,
Hofacker IL, et al: RNA maps reveal new RNA classes and a possible
function for pervasive transcription. Science. 316:1484–1488. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Young TL, Matsuda T and Cepko CL: The
noncoding RNA taurine upregulated gene 1 is required for
differentiation of the murine retina. Curr Biol. 15:501–512. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han Y, Liu Y, Gui Y and Cai Z: Long
intergenic non-coding RNA TUG1 is overexpressed in urothelial
carcinoma of the bladder. J Surg Oncol. 107:555–559. 2013.
View Article : Google Scholar
|
|
20
|
Xu Y, Wang J, Qiu M and Xu L, Li M, Jiang
F, Yin R and Xu L: Upregulation of the long noncoding RNA TUG1
promotes proliferation and migration of esophageal squamous cell
carcinoma. Tumour Biol. 36:1643–1651. 2015. View Article : Google Scholar
|
|
21
|
Zhang Q, Geng PL, Yin P, Wang XL, Jia JP
and Yao J: Downregulation of long non-coding RNA TUG1 inhibits
osteosarcoma cell proliferation and promotes apoptosis. Asian Pac J
Cancer Prev. 14:2311–2315. 2013. View Article : Google Scholar
|
|
22
|
Zhao XB and Ren GS: LncRNA
taurine-upregulated gene 1 promotes cell proliferation by
inhibiting microRNA-9 in MCF-7 cells. J Breast Cancer. 19:349–357.
2016. View Article : Google Scholar
|
|
23
|
Wang Y, Yang T, Zhang Z, Lu M, Zhao W,
Zeng X and Zhang W: Long non-coding RNA TUG1 promotes migration and
invasion by acting as a ceRNA of miR-335-5p in osteosarcoma cells.
Cancer Sci. 108:859–867. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang H, Yu Y, Fan S and Luo L: Knockdown
of long noncoding RNA TUG1 inhibits the proliferation and cellular
invasion of osteosarcoma cells by sponging miR-153. Oncol Res.
Apr;12:2017Epub ahead of print.
|
|
25
|
Wang Q and Chen Q: Role of taurine
upregulated gene 1 as a predictor of poor outcome in osteosarcoma.
J Cancer Res Ther. (In press). http://www.cancerjournal.net/preprintarticle.asp?id=172585;type=0.
|
|
26
|
Ma B, Li M, Zhang L, Huang M, Lei JB, Fu
GH, Liu CX, Lai QW, Chen QQ and Wang YL: Upregulation of long
non-coding RNA TUG1 correlates with poor prognosis and disease
status in osteosarcoma. Tumour Biol. 37:4445–4455. 2016. View Article : Google Scholar
|
|
27
|
Feng YB, Liu XP, Li XL, Cao GL, Zhang P
and Tian FM: LncRNA TUG1 is upregulated and promotes cell
proliferation in osteosarcoma. Open Med (Wars). 11:163–167.
2016.
|
|
28
|
Namløs HM, Meza-Zepeda LA, Barøy T,
Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H,
Cleton-Jansen AM and Myklebost O: Modulation of the osteosarcoma
expression phenotype by microRNAs. PLoS One. 7:e480862012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lei H, Gao Y and Xu X: LncRNA TUG1
influences papillary thyroid cancer cell proliferation, migration
and EMT formation through targeting miR-145. Acta Biochim Biophys
Sin (Shanghai). 22:1–10. 2017.
|
|
30
|
Liu L, Chen X, Zhang Y, Hu Y, Shen X and
Zhu W: Long non-coding RNA TUG1 promotes endometrial cancer
development via inhibiting miR-299 and miR-34a-5p. Oncotarget.
8:31386–31394. 2017.PubMed/NCBI
|
|
31
|
Li J, An G, Zhang M and Ma Q: Long
non-coding RNA TUG1 acts as a miR-26a sponge in human glioma cells.
Biochem Biophys Res Commun. 477:743–748. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao M, Huang J, Gui K, Xiong M, Cai G, Xu
J, Wang K, Liu D, Zhang X and Yin W: The downregulation of miR-144
is associated with the growth and invasion of osteosarcoma cells
through the regulation of TAGLN expression. Int J Mol Med.
34:1565–1572. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang W, Zhou X and Wei M: MicroRNA-144
suppresses osteosarcoma growth and metastasis by targeting ROCK1
and ROCK2. Oncotarget. 6:10297–10308. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang K, Zhang Y, Ren K, Zhao G, Yan K and
Ma B: MicroRNA-101 inhibits the metastasis of osteosarcoma cells by
downregulation of EZH2 expression. Oncol Rep. 32:2143–2149. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu Z, Tang J, Wang J, Duan G, Zhou L and
Zhou X: MiR-138 acts as a tumor suppressor by targeting EZH2 and
enhances cisplatin-induced apoptosis in osteosarcoma cells. PLoS
One. 11:e01500262016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sun R, Shen J, Gao Y, Zhou Y, Yu Z,
Hornicek F, Kan Q and Duan Z: Overexpression of EZH2 is associated
with the poor prognosis in osteosarcoma and function analysis
indicates a therapeutic potential. Oncotarget. 7:38333–38346. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lv Y-F, Yan G-N, Meng G, Zhang X and Guo
Q-N: Enhancer of zeste homolog 2 silencing inhibits tumor growth
and lung metastasis in osteosarcoma. Sci Rep. 5:129992015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ma L, Bajic VB and Zhang Z: On the
classification of long non-coding RNAs. RNA Biol. 10:925–933. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fatica A and Bozzoni I: Long non-coding
RNAs: New players in cell differentiation and development. Nat Rev
Genet. 15:7–21. 2014. View
Article : Google Scholar
|
|
40
|
Nagarajan R, Kamruzzaman A, Ness KK,
Marchese VG, Sklar C, Mertens A, Yasui Y, Robison LL and Marina N:
Twenty years of follow-up of survivors of childhood osteosarcoma: A
report from the Childhood Cancer Survivor Study. Cancer.
117:625–634. 2011. View Article : Google Scholar
|
|
41
|
Bielack S, Carrle D and Casali PG; ESMO
Guidelines Working Group: Osteosarcoma: ESMO clinical
recommendations for diagnosis, treatment and follow-up. Ann Oncol.
20(Suppl 4): 137–139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Eccles SA and Welch DR: Metastasis: Recent
discoveries and novel treatment strategies. Lancet. 369:1742–1757.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chan LH, Wang W, Yeung W, Deng Y, Yuan P
and Mak KK: Hedgehog signaling induces osteosarcoma development
through Yap1 and H19 overexpression. Oncogene. 33:4857–4866. 2014.
View Article : Google Scholar
|
|
44
|
Dong Y, Liang G, Yuan B, Yang C, Gao R and
Zhou X: MALAT1 promotes the proliferation and metastasis of
osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol.
36:1477–1486. 2015. View Article : Google Scholar
|
|
45
|
Wang Y, Yao J, Meng H, Yu Z, Wang Z, Yuan
X, Chen H and Wang A: A novel long non-coding RNA,
hypoxia-inducible factor-2α promoter upstream transcript, functions
as an inhibitor of osteosarcoma stem cells in vitro. Mol Med Rep.
11:2534–2540. 2015. View Article : Google Scholar
|
|
46
|
Lv J, Fan HX, Zhao XP, Lv P, Fan JY, Zhang
Y, Liu M and Tang H: Long non-coding RNA Unigene56159 promotes
epithelial-mesenchymal transition by acting as a ceRNA of
miR-140-5p in hepatocellular carcinoma cells. Cancer Lett.
382:166–175. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tay Y, Rinn J and Pandolfi PP: The
multilayered complexity of ceRNA crosstalk and competition. Nature.
505:344–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ji TT, Huang X, Jin J, Pan SH and Zhuge
XJ: Inhibition of long non-coding RNA TUG1 on gastric cancer cell
transference and invasion through regulating and controlling the
expression of miR-144/c-Met axis. Asian Pac J Trop Med. 9:508–512.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tan J, Qiu K, Li M and Liang Y:
Double-negative feedback loop between long non-coding RNA TUG1 and
miR-145 promotes epithelial to mesenchymal transition and
radioresistance in human bladder cancer cells. FEBS Lett.
589:3175–3181. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chochi Y, Kawauchi S, Nakao M, Furuya T,
Hashimoto K, Oga A, Oka M and Sasaki K: A copy number gain of the
6p arm is linked with advanced hepatocellular carcinoma: An
array-based comparative genomic hybridization study. J Pathol.
217:677–684. 2009. View Article : Google Scholar
|
|
51
|
Cao R and Zhang Y: The functions of
E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr
Opin Genet Dev. 14:155–164. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cha TL, Zhou BP, Xia W, Wu Y, Yang CC,
Chen CT, Ping B, Otte AP and Hung MC: Akt-mediated phosphorylation
of EZH2 suppresses methylation of lysine 27 in histone H3. Science.
310:306–310. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Croonquist PA and Van Ness B: The polycomb
group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene
that influences myeloma cell growth and the mutant ras phenotype.
Oncogene. 24:6269–6280. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kleer CG, Cao Q, Varambally S, Shen R, Ota
I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Richter GH, Plehm S, Fasan A, Rössler S,
Unland R, Bennani-Baiti IM, Hotfilder M, Löwel D, von Luettichau I,
Mossbrugger I, et al: EZH2 is a mediator of EWS/FLI1 driven tumor
growth and metastasis blocking endothelial and neuroectodermal
differentiation. Proc Natl Acad Sci USA. 106:5324–5329. 2009.
View Article : Google Scholar
|
|
56
|
Varambally S, Dhanasekaran SM, Zhou M,
Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt
RG, Otte AP, et al: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature. 419:624–629. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Nolz JC, Gomez TS and Billadeau DD: The
Ezh2 methyltransferase complex: Actin up in the cytosol. Trends
Cell Biol. 15:514–517. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH,
Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, et al: The putative
tumour suppressor microRNA-124 modulates hepatocellular carcinoma
cell aggressiveness by repressing ROCK2 and EZH2. Gut. 61:278–289.
2012. View Article : Google Scholar
|
